Tectonic Therapeutic, Inc. (NASDAQ:TECX) shareholders (or potential shareholders) will be happy to see that the Independent Director, Timothy Springer, recently bought a whopping US$10m worth of stock, at a price of US$33.59. While that only increased their holding size by 7.0%, it is still a big swing by our standards.

Check out our latest analysis for Tectonic Therapeutic

Tectonic Therapeutic Insider Transactions Over The Last Year

Notably, that recent purchase by Timothy Springer is the biggest insider purchase of Tectonic Therapeutic shares that we've seen in the last year. We do like to see buying, but this purchase was made at well below the current price of US$38.74. Because the shares were purchased at a lower price, this particular buy doesn't tell us much about how insiders feel about the current share price.

Timothy Springer bought a total of 350.00k shares over the year at an average price of US$32.91. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

Tectonic Therapeutic is not the only stock that insiders are buying. For those who like to find small cap companies at attractive valuations, this free list of growing companies with recent insider purchasing, could be just the ticket.

Insider Ownership

Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. I reckon it's a good sign if insiders own a significant number of shares in the company. Tectonic Therapeutic insiders own about US$236m worth of shares (which is 41% of the company). This kind of significant ownership by insiders does generally increase the chance that the company is run in the interest of all shareholders.

So What Does This Data Suggest About Tectonic Therapeutic Insiders?

It's certainly positive to see the recent insider purchase. And the longer term insider transactions also give us confidence. However, we note that the company didn't make a profit over the last twelve months, which makes us cautious. Once you factor in the high insider ownership, it certainly seems like insiders are positive about Tectonic Therapeutic. Nice! So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company. To that end, you should learn about the 4 warning signs we've spotted with Tectonic Therapeutic (including 2 which can't be ignored).

If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.